secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2022-05-26T23:59:59+00:00
Accession:  0001564590-22-021434
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma's PC14586 shows 30% partial response in higher dose cohorts at ASCO
------------------------------------------------------------------------------

- Abstract reports 3/10 (30%) partial responses in patients treated in higher dose cohorts of Phase 1/2 PYNNACLE trial.
- Data from 29 patients (21 evaluable) across multiple tumor types with p53 Y220C mutation; safety profile well-tolerated.
- Dose-proportional increases in Cmax and AUC observed; updated data to be presented in oral session on June 7, 2022.
- Company to host investor webcast on June 7 at 6:30 PM CDT to review data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000156459022021434/0001564590-22-021434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000156459022021434/pmvp-8k_20220526.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-021434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer